Skip to main content

Table 4 Effect of baseline characteristics on GC prescriptions according to prescriber tendency

From: Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study

Variable Low prescriber group (OR, 95 % CI) High prescriber group (OR, 95 % CI) p value**
Demographics    
Age (decades) 1.15, 1.11–1.20* 1.26, 1.23–1.29* <0.001
Gender (female) 0.98, 0.87–1.10 0.89, 0.82–0.97* 0.211
Current smoker (versus never) 1.09, 1.02–1.17* 1.07, 1.02–1.13* 0.744
GC-associated comorbidities    
Osteoporosis 1.49, 1.14–1.95* 1.84, 1.50–2.25* 0.225
Avascular necrosis 2.28, 0.32–16.22 1.84, 0.36–9.51 0.870
Myopathy 2.29, 0.57–9.15 1.23, 0.45–3.38 0.479
Diabetes mellitus 0.88, 0.72–1.08 1.02, 0.88–1.18 0.257
Cardiovascular disease 1.38, 1.04–1.84* 1.62, 1.31–2.00* 0.373
Hypertension 1.08, 0.95–1.24 1.29, 1.17–1.41* 0.039
Hyperlipidaemia 1.10, 0.92–1.31 1.07, 0.94–1.22 0.829
Peptic ulcer disease 1.36, 1.06–1.74* 1.33, 1.09–1.63* 0.910
Pancreatitis 1.00, 0.49–2.05 1.44, 0.81–2.54 0.442
Depression 1.09, 0.96–1.23 1.09, 0.99–1.20 0.994
Insomnia 1.27, 1.08–1.50* 1.36, 1.20–1.54* 0.548
Psychosis 1.14, 0.60–2.17 1.29, 0.78–2.14 0.767
Prior use    
GC prescription prior to follow up 6.52, 5.51–7.71* 11.76, 10.24–13.51* <0.001
  1. GC glucocorticoid, OR odds ratio, CI confidence interval
  2. *Significant predictors of GC prescriptions (unadjusted)
  3. ** p value indicates significance of any differing effect between high and low prescriber groups